Drugs / CD19-CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05645601 | Dec 2022 → May 2024 | B-cell neoplasm | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05645601 ↗ |
| Known as | JD010 | “JD010 injection is a CD19-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) derived from a healthy donor” NCT05645601 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor NK-cell (CAR-NK) therapy” NCT05645601 ↗ |
| Target | CD19 | “CD19-Targeted” NCT05645601 ↗ |